MOR Dhuwit awis perusahaan MorphoSys Corp

Simbol resmi perusahaan MorphoSys AG (MOR)

MorphoSys AG relies on the HuCAL and Ylanthia ecosystem, creating a strong lock-in for third-party developers to its protein libraries. The cash position, indicated by 0.68, links this potential to robotic complexes that autonomously conduct thousands of tests. Patents for myelofibrosis and support from a Swiss giant have formed a powerful technological moat, protecting the company from new startups.

Aset likuid perusahaan: MorphoSys Corporation (MOR) kanggo 04.07.2022 - 10.08.2024

Rincian analitis perusahaan MorphoSys AG

- nilai saham lan prakiraan konsensus rega:
Analisis wiwitan perusahaan:MOR morphosys.com
Produk merek morphosys.com

This indicator reflects the actual volume of liquid assets, allowing for an assessment of the business's operational resilience outside the framework of quarterly reporting. By analyzing the free cash flow chart, an investor can observe real-time capital dynamics. The metric aggregates balances in current accounts and cash equivalents, subtracting current liabilities. For MorphoSys AG (MOR), this reserve is critically important during the joint promotion of pelabresib with Novartis. Sufficient cash levels ensure the uninterrupted funding of clinical trials until the commercial launch of the therapy.

Pesaing MorphoSys AG

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|Aset likuid perusahaan Aura Bio|Volume dana dhuwit perusahaan CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Cadangan dhuwit perusahaan|SELLAS Life Sciences Group - Volume dana dhuwit perusahaan|ACTU - Volume dana dhuwit perusahaan|CTOR: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Volume dana dhuwit perusahaan|Fate Therapeutics, Inc. (FATE) - Aset likuid perusahaan|Dhuwit awis perusahaan WHWK (Aadi Bioscience, Inc.)|Aset likuid perusahaan TScan Therapeutics, Inc.|Volume dana dhuwit perusahaan CSBR (Champions Oncology Corp)|Gunggung dana dhuwit perusahaan XBIT (XBiotech USA)|CVM - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Dana dhuwit perusahaan|ARTV: Gunggung dana dhuwit perusahaan|ANL (adlainortye.com) - Volume dana dhuwit perusahaan|VERU: Sisa dhuwit perusahaan|Dhuwit awis perusahaan TPST (Tempest Tx)|Dhuwit awis perusahaan Xilio XLO|Volume dana dhuwit perusahaan RENB (Renovaro)|Volume dana dhuwit perusahaan Mural Bio MURA|Kairos Pharma Ltd - Volume dana dhuwit perusahaan|OnKure Therapeutics (OKUR) - Dhuwit awis perusahaan|GDTC: Volume dana dhuwit perusahaan|Curis Inc. - Sisa dhuwit perusahaan|Dana dhuwit perusahaan apollomicsinc.com|THAR: Sisa dhuwit perusahaan|Dana dhuwit perusahaan Advanced Biomed Corp (ADVB)|GNPX (Genprex, Inc) - Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan CLDI (Calidi Biotherapeutics)|sunshinebiopharma.com (SBFM) - Cadangan dhuwit perusahaan|Xenetic Bio - Volume dana dhuwit perusahaan|SLRX (Salarius Pharmaceuticals, Inc.) - Dhuwit awis lan setara dhuwit awis perusahaan|PPBT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan American Oncology Network Inc|BGNE (beigene.com) - Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan CKPT (Checkpoint Therapeutics)|Dhuwit awis perusahaan ELEV (Elevation Oncology Inc.)|iCAD - Dhuwit awis lan setara dhuwit awis perusahaan|Ikena Oncology Inc. - Dhuwit awis perusahaan|Notable Labs Corp (NTBL) - Cadangan dhuwit perusahaan|VIRX: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan